NOVONIX Limited filings document foreign-issuer reports furnished on Form 6-K, with exhibits drawn from ASX announcements and corporate notices. The record includes disclosures on annual general meeting presentations and voting results, material-event updates, material agreements, operating and financial results, and governance matters tied to the company's battery materials business.
Capital-structure filings cover applications for quotation of ordinary fully paid securities, securities issued from option exercises or convertible-security conversions, performance rights, and director interest notices. These filings also record shareholder voting matters and formal updates relevant to NOVONIX's ADR and foreign-issuer reporting framework.
NOVONIX Ltd director Robert J. Natter reported internal transfers of company shares between accounts he beneficially owns. On the reported date, three “J” code transactions moved a total of 460,686 ordinary shares among direct holdings and family trusts at a stated price of $0.0000 per share.
A footnote explains these were administrative transfers and did not change his overall economic interest in NOVONIX securities. He also holds share rights over 195,938 underlying ordinary shares with a stated exercise price of $0.0000 and an expiration date of December 31, 2027.
NOVONIX Ltd director Robert J. Natter reported internal transfers of company shares between accounts he beneficially owns. On the reported date, three “J” code transactions moved a total of 460,686 ordinary shares among direct holdings and family trusts at a stated price of $0.0000 per share.
A footnote explains these were administrative transfers and did not change his overall economic interest in NOVONIX securities. He also holds share rights over 195,938 underlying ordinary shares with a stated exercise price of $0.0000 and an expiration date of December 31, 2027.
NOVONIX Ltd director Tony Bellas reported his derivative holdings of share rights linked to ordinary shares. The filing shows 195,938 underlying ordinary shares tied to these share rights at an exercise price of $0.0000 per share, exercisable from December 31, 2026 and expiring on December 31, 2027. No purchases or sales were reported; this entry updates his position in these rights.
NOVONIX Ltd director Tony Bellas reported his derivative holdings of share rights linked to ordinary shares. The filing shows 195,938 underlying ordinary shares tied to these share rights at an exercise price of $0.0000 per share, exercisable from December 31, 2026 and expiring on December 31, 2027. No purchases or sales were reported; this entry updates his position in these rights.
NOVONIX Ltd director Jean Oelwang reported a derivative holding of 195,938 share rights linked to ordinary shares. These share rights have an exercise price of $0.0000 and are scheduled to expire on December 31, 2027. The filing shows 195,938 underlying ordinary shares associated with this position, with no buy or sell transactions indicated in the provided data.
NOVONIX Ltd director Jean Oelwang reported a derivative holding of 195,938 share rights linked to ordinary shares. These share rights have an exercise price of $0.0000 and are scheduled to expire on December 31, 2027. The filing shows 195,938 underlying ordinary shares associated with this position, with no buy or sell transactions indicated in the provided data.
NOVONIX Ltd director Ronald C. Edmonds reported his holdings of share rights linked to the company’s ordinary shares. The filing shows share rights over 195,938 underlying ordinary shares with an exercise price of $0.00 per share, exercisable from December 31, 2026 and expiring on December 31, 2027. This entry reflects a reported position rather than a new purchase or sale.
NOVONIX Ltd director Ronald C. Edmonds reported his holdings of share rights linked to the company’s ordinary shares. The filing shows share rights over 195,938 underlying ordinary shares with an exercise price of $0.00 per share, exercisable from December 31, 2026 and expiring on December 31, 2027. This entry reflects a reported position rather than a new purchase or sale.
NOVONIX Ltd director Burrow Sharan reported a holding of 195,938 share rights linked to ordinary shares. These rights have a zero exercise price and are scheduled to become exercisable on December 31, 2026, with an expiration date of December 31, 2027. The filing reflects a position update rather than a new buy or sell transaction.
NOVONIX Ltd director Burrow Sharan reported a holding of 195,938 share rights linked to ordinary shares. These rights have a zero exercise price and are scheduled to become exercisable on December 31, 2026, with an expiration date of December 31, 2027. The filing reflects a position update rather than a new buy or sell transaction.
NOVONIX Ltd director and Chief Executive Officer Michael O'Kronley reported his existing derivative holdings in the form of performance rights. These rights relate to 5,862,567 underlying ordinary shares, have an exercise price of $0.0000, become exercisable on December 31, 2028, and expire on December 31, 2029. The entry is recorded as a holding, with no buy or sell transaction reported.
NOVONIX Ltd director and Chief Executive Officer Michael O'Kronley reported his existing derivative holdings in the form of performance rights. These rights relate to 5,862,567 underlying ordinary shares, have an exercise price of $0.0000, become exercisable on December 31, 2028, and expire on December 31, 2029. The entry is recorded as a holding, with no buy or sell transaction reported.
Novonix Limited filed a Form 6-K that includes an ASX Appendix 3Y detailing a change in director interests for Michael O’Kronley. The filing records the issue of performance rights to the director following shareholder approval at the AGM held on 15 April 2026.
After this change, Michael O’Kronley holds 9,586,538 performance rights. The notice also confirms that the interests were not traded during a closed period, so no special trading clearance was required.
Novonix Limited filed a Form 6-K that includes an ASX Appendix 3Y detailing a change in director interests for Michael O’Kronley. The filing records the issue of performance rights to the director following shareholder approval at the AGM held on 15 April 2026.
After this change, Michael O’Kronley holds 9,586,538 performance rights. The notice also confirms that the interests were not traded during a closed period, so no special trading clearance was required.
NOVONIX Limited reports key strategic and cash developments for the quarter ended 31 March 2026. The U.S. Government certified the company’s Riverside project for a previously allocated US$103 million Section 48C advanced manufacturing tax credit, expected when the first 11,000 tonnes per annum of capacity is placed in service before 7 April 2028, with credits that can be sold to a third party.
NOVONIX signed a binding term sheet to divest its Battery Technology Solutions business while retaining a 15% equity stake, and secured exclusive rights to evaluate buying adjacent Riverside land for US$26.5 million, a move the company says could enable more than US$200 million in potential capital savings if a 50,000 tpa build-out is consolidated on one site. The company also highlighted revised mass production timing for Panasonic Energy to the second half of 2027 and a changing U.S. trade environment for anode materials.
Financially, NOVONIX posted a quarterly operating cash outflow of US$14.4 million and invested US$6.8 million in property, plant, and equipment, mainly at Riverside. Cash and cash equivalents were US$57.1 million at quarter-end, equating to an estimated 4.0 quarters of funding based on recent cash usage. The company also received notice from Nasdaq that its ADRs no longer meet the US$1.00 minimum bid price requirement and is assessing options such as adjusting the ADR-to-ordinary share ratio.
NOVONIX Limited reports key strategic and cash developments for the quarter ended 31 March 2026. The U.S. Government certified the company’s Riverside project for a previously allocated US$103 million Section 48C advanced manufacturing tax credit, expected when the first 11,000 tonnes per annum of capacity is placed in service before 7 April 2028, with credits that can be sold to a third party.
NOVONIX signed a binding term sheet to divest its Battery Technology Solutions business while retaining a 15% equity stake, and secured exclusive rights to evaluate buying adjacent Riverside land for US$26.5 million, a move the company says could enable more than US$200 million in potential capital savings if a 50,000 tpa build-out is consolidated on one site. The company also highlighted revised mass production timing for Panasonic Energy to the second half of 2027 and a changing U.S. trade environment for anode materials.
Financially, NOVONIX posted a quarterly operating cash outflow of US$14.4 million and invested US$6.8 million in property, plant, and equipment, mainly at Riverside. Cash and cash equivalents were US$57.1 million at quarter-end, equating to an estimated 4.0 quarters of funding based on recent cash usage. The company also received notice from Nasdaq that its ADRs no longer meet the US$1.00 minimum bid price requirement and is assessing options such as adjusting the ADR-to-ordinary share ratio.
Novonix Limited is reporting the issue and ASX quotation of additional ordinary fully paid shares resulting from the conversion of performance rights under an employee incentive scheme. The new shares are in an existing quoted class and will rank equally with other ordinary shares from their issue date.
No cash is being paid for these shares, with the consideration valued at approximately AUD 0.265 per share. Following this quotation, Novonix states that its quoted ordinary share capital on ASX will comprise 861,442,940 ordinary fully paid shares, alongside several unquoted classes including performance rights, options and convertible notes.
Novonix Limited is reporting the issue and ASX quotation of additional ordinary fully paid shares resulting from the conversion of performance rights under an employee incentive scheme. The new shares are in an existing quoted class and will rank equally with other ordinary shares from their issue date.
No cash is being paid for these shares, with the consideration valued at approximately AUD 0.265 per share. Following this quotation, Novonix states that its quoted ordinary share capital on ASX will comprise 861,442,940 ordinary fully paid shares, alongside several unquoted classes including performance rights, options and convertible notes.
NOVONIX Limited filed an amended Form 6-K to correct formatting in its previously furnished AGM presentation, confirming no substantive changes to the underlying content. The filing also provides the Chairman’s address, updated strategy, and detailed voting results from the April 15, 2026 Annual General Meeting.
The Chairman highlights 2025 as a key year, including delivery of the first mass-production, commercial-grade synthetic graphite sample and installation of four graphitization furnaces at the Riverside facility in Chattanooga to support Panasonic Energy qualification. NOVONIX expects mass production of industrial-grade synthetic graphite to begin in 2026 and now anticipates mass production of battery-grade anode material for Panasonic Energy in the second half of 2027.
The company executed a funding agreement with Yorkville Advisors for access to US$100 million in convertible debentures, sold its Mt Dromedary natural graphite project, and agreed a binding term sheet to divest its Battery Technology Solutions division while retaining 15% ownership. NOVONIX reports contracted offtakes including a four‑year, 10,000‑tonne commitment and a five‑year, minimum 32,000‑tonne commitment, both subject to successful qualification. All AGM resolutions, including director re‑elections, performance rights, share rights, and additional 10% placement capacity, were carried by strong majorities.
NOVONIX Limited filed an amended Form 6-K to correct formatting in its previously furnished AGM presentation, confirming no substantive changes to the underlying content. The filing also provides the Chairman’s address, updated strategy, and detailed voting results from the April 15, 2026 Annual General Meeting.
The Chairman highlights 2025 as a key year, including delivery of the first mass-production, commercial-grade synthetic graphite sample and installation of four graphitization furnaces at the Riverside facility in Chattanooga to support Panasonic Energy qualification. NOVONIX expects mass production of industrial-grade synthetic graphite to begin in 2026 and now anticipates mass production of battery-grade anode material for Panasonic Energy in the second half of 2027.
The company executed a funding agreement with Yorkville Advisors for access to US$100 million in convertible debentures, sold its Mt Dromedary natural graphite project, and agreed a binding term sheet to divest its Battery Technology Solutions division while retaining 15% ownership. NOVONIX reports contracted offtakes including a four‑year, 10,000‑tonne commitment and a five‑year, minimum 32,000‑tonne commitment, both subject to successful qualification. All AGM resolutions, including director re‑elections, performance rights, share rights, and additional 10% placement capacity, were carried by strong majorities.